Thus, to determine whether there is an association between HRD1 and Vimentin at the protein level, we performed proteomic analysis on mass spectrometry data from the Clinical Proteomic Tumor Analysis Consortium (Fig. 2b) and found that HRD1 expression is in a prominently negative correlation with Vimentin in breast cancer samples of the CTPAC project (Fig. 2c). The gene discussed is VIM; the disease is neoplasm.